Intact Investment Management Inc. Has $933,000 Holdings in DexCom, Inc. (NASDAQ:DXCM)

Intact Investment Management Inc. lifted its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 23.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 12,000 shares of the medical device company’s stock after purchasing an additional 2,300 shares during the period. Intact Investment Management Inc.’s holdings in DexCom were worth $933,000 as of its most recent filing with the SEC.

Other hedge funds also recently modified their holdings of the company. Blue Whale Capital LLP lifted its holdings in shares of DexCom by 91.9% during the third quarter. Blue Whale Capital LLP now owns 236,000 shares of the medical device company’s stock worth $15,821,000 after purchasing an additional 113,000 shares during the period. Motley Fool Asset Management LLC lifted its holdings in shares of DexCom by 168.7% during the third quarter. Motley Fool Asset Management LLC now owns 272,622 shares of the medical device company’s stock worth $17,993,000 after purchasing an additional 171,150 shares during the period. Watts Gwilliam & Co. LLC acquired a new position in shares of DexCom during the fourth quarter worth $3,334,000. Congress Asset Management Co. lifted its holdings in shares of DexCom by 5,456.9% during the fourth quarter. Congress Asset Management Co. now owns 1,356,941 shares of the medical device company’s stock worth $105,529,000 after purchasing an additional 1,332,522 shares during the period. Finally, Janney Montgomery Scott LLC lifted its holdings in shares of DexCom by 2,226.6% during the fourth quarter. Janney Montgomery Scott LLC now owns 232,543 shares of the medical device company’s stock worth $18,085,000 after purchasing an additional 222,548 shares during the period. Institutional investors and hedge funds own 97.75% of the company’s stock.

DexCom Trading Up 3.2 %

DXCM opened at $70.69 on Friday. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28. DexCom, Inc. has a fifty-two week low of $62.34 and a fifty-two week high of $142.00. The firm has a market capitalization of $27.62 billion, a PE ratio of 49.43, a P/E/G ratio of 2.30 and a beta of 1.28. The company’s 50-day moving average is $83.99 and its 200 day moving average is $76.89.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. As a group, research analysts predict that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the stock. Canaccord Genuity Group boosted their target price on shares of DexCom from $99.00 to $103.00 and gave the company a “buy” rating in a report on Friday, February 14th. Robert W. Baird upgraded shares of DexCom from a “neutral” rating to an “outperform” rating and boosted their target price for the company from $86.00 to $104.00 in a report on Thursday, January 16th. Citigroup boosted their target price on shares of DexCom from $101.00 to $104.00 and gave the company a “buy” rating in a report on Tuesday, March 4th. Baird R W upgraded shares of DexCom from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 16th. Finally, Wells Fargo & Company restated an “overweight” rating on shares of DexCom in a report on Saturday, March 8th. Four investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, DexCom presently has a consensus rating of “Moderate Buy” and an average price target of $99.82.

Insider Buying and Selling at DexCom

In other DexCom news, COO Jacob Steven Leach sold 14,076 shares of the stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total value of $990,668.88. Following the completion of the sale, the chief operating officer now owns 313,497 shares in the company, valued at approximately $22,063,918.86. This trade represents a 4.30 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Kevin R. Sayer sold 33,359 shares of the stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the completion of the sale, the chief executive officer now owns 319,037 shares of the company’s stock, valued at approximately $27,727,505.67. This trade represents a 9.47 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 104,657 shares of company stock worth $8,019,422. Insiders own 0.30% of the company’s stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.